Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 44,958 |
|
|||||
| News | - | ||||||
| Day High | 9.115 | Low High |
|||||
| Day Low | 8.6101 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Coya Therapeutics Inc | COYA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.38 | -4.20% | 8.67 | 16:16:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.00 | 8.6101 | 9.115 | 8.67 | 9.05 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,295 | 44,958 | US$ 8.86 | US$ 398,506 | - | 3.21 - 10.6899 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:40:16 | 12 | US$ 8.87 | USD |
Coya Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 86.96M | 10.03M | - | 6M | -7.99M | -0.80 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Coya Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COYA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.05 | 9.22 | 8.05 | 8.50 | 58,603 | 0.62 | 7.70% |
| 1 Month | 9.82 | 10.23 | 7.81 | 8.80 | 55,885 | -1.15 | -11.71% |
| 3 Months | 5.99 | 10.6899 | 5.99 | 9.17 | 101,590 | 2.68 | 44.74% |
| 6 Months | 4.89 | 10.6899 | 4.40 | 8.16 | 74,619 | 3.78 | 77.30% |
| 1 Year | 4.88 | 10.6899 | 3.21 | 6.33 | 85,922 | 3.79 | 77.66% |
| 3 Years | 4.75 | 10.6899 | 3.21 | 6.18 | 69,812 | 3.92 | 82.53% |
| 5 Years | 4.75 | 10.6899 | 3.21 | 6.18 | 69,812 | 3.92 | 82.53% |
Coya Therapeutics Description
| Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. |
